[1] Lozano R, Naghavi M, Foreman K, et al.Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010[J]. Lancet,2012, 380(9859):2095-2128.
[2] Lok AS, McMahon BJ, Brown RS Jr, et al. Antiviral the-rapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis[J]. Hepatology,2016, 63(1):284-306.
[3] Hou J, Wang G, Wang F, et al.Guideline of Prevention and Treatment for Chronic Hepatitis B(2015 Update)[J]. J Clin Transl Hepatol,2017,5(4):297-318.
[4] Nassal M.HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B[J]. Gut,2015,64(12):1972-1984.
[5] Seeger C, Mason WS.Hepatitis B virus biology[J]. Microbiol Mol Biol Rev,2000,64(1):51-68.
[6] Deguchi M, Yamashita N, Kagita M, et al.Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay[J]. J Virol Methods,2004,115(2):217-222.
[7] Liaw YF, Sheen IS, Chen TJ, et al.Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study[J]. Hepatology,1991,13(4):627-631.
[8] Chang TT, Lai CL, Kew Yoon S, et al.Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B[J]. Hepatology,2010,51(2):422-430.
[9] Seto WK, Hui AJ, Wong VW, et al.Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study[J]. Gut,2015,64(4):667-672.
[10] Hsu YC, Mo LR, Chang CY, et al.Association Between Serum Level of Hepatitis B Surface Antigen at End of Entecavir Therapy and Risk of Relapse in E Antigen-Negative Patients[J]. Clin Gastroenterol Hepatol,2016,14(10):1490-1498.
[11] Qiu YW, Huang LH, Yang WL, et al.Hepatitis B surface antigen quantification at hepatitis B e antigen seroconversion predicts virological relapse after the cessation of entecavir treatment in hepatitis B e antigen-positive patients[J]. Int J Infect Dis,2016,43:43-48.
[12] Seto WK, Wong DK, Fung J, et al.Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy[J]. Hepatology,2013, 58(3):923-931.
[13] Thompson AJ, Nguyen T, Iser D, et al.Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahe-patic hepatitis B virus markers[J]. Hepatology,2010,51(6):1933-1944.
[14] Sonneveld MJ, Hansen BE, Piratvisuth T, et al.Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels[J]. Hepatology,2013,58(3):872-880.
[15] Sonneveld MJ, Rijckborst V, Boucher CA, et al.Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline[J]. Hepa-tology,2010,52(4):1251-1257.
[16] Manesis EK, Papatheodoridis GV, Tiniakos DG, et al.Hepatitis B surface antigen: relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B[J]. J Hepatol,2011,55(1):61-68.
[17] Cao Z, Liu Y, Ma L, et al. A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated-interferon alpha[J]. Hepatology,2017 Oct,66(4):1058-1066.
[18] Ning Q, Han M, Sun Y, et al.Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial)[J]. J Hepatol,2014,61(4):777-784.
[19] Hu P, Jia S, Zhang WH, et al.A multi-center randomized study on the efficacy and safety of switching to peginterferon alpha-2a (40KD) for 48 or 96 weeks in HBeAg positive CHB patients with a prior NUC history for 1 to 3 years: an interim analysis of NEW SWITCH study[J]. Hepatology,2014,60(6):1273a-1274a.
[20] Wang J, Shen T, Huang X, et al.Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound[J]. J Hepatol,2016,65(4):700-710.
[21] van Bömmel F, Bartens A, Mysickova A, et al. Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors[J]. Hepatology,2015,61(1):66-76.
[22] Tsuge M, Murakami E, Imamura M, et al.Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients[J]. J Gastroenterol,2013,48(10):1188-1204.
[23] Halgand B, Desterke C, Rivière L, et al.Hepatitis B Virus Pregenomic RNA in Hepatocellular Carcinoma: A Nosological and Prognostic Determinant[J]. Hepatology,2018,67(1):86-96.
[24] Ryu DK, Ahn Y, Ryu WS, et al.Development of a novel hepatitis B virus encapsidation detection assay by viral nucleocapsid-captured quantitative RT-PCR[J]. Biotechniques,2015,59(5):287-293.
[25] Wang J, Yu Y, Li G, et al. Relationship between serum HBV-RNA levels and intrahepatic viral as well as histologic activity markers in entecavir-treated patients[J]. J Hepatol,2017,pii: 32261-3264.
[26] Jansen L, Kootstra NA, van Dort KA, et al. Hepatitis B Virus Pregenomic RNA Is Present in Virions in Plasma and Is Associated With a Response to Pegylated Interferon Alfa-2a and Nucleos(t)ide Analogues[J]. J Infect Dis,2016,213(2):224-232. |
